Last quarter (Q2 2023), Kinnate Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Kinnate Biopharma's net income was $-31.92M. See Kinnate Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 67.48M	$ -118.52M	$ -90.11M	$ 36.00M	$ 12.01M	$ 7.63M
Operating Income	$ -132.89M	$ -118.57M	$ -90.14M	$ -36.00M	$ -12.01M	$ -7.63M
Net Non Operating Interest Income Expense	$ 2.83M	$ 2.25M	-	$ 240.00K	$ 43.00K	$ 0.00
Other Income Expense	$ -1.58M	-	$ -348.00K	$ -5.00K	-	-
Pretax Income	$ -127.21M	$ -116.32M	$ -89.80M	$ -35.76M	$ -11.97M	$ -7.63M
Tax Provision	$ -2.14M	$ -2.14M	$ -548.00K	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -127.21M	$ -116.32M	$ -89.80M	$ -35.76M	$ -9.94M	$ -7.63M
Basic EPS	$ -2.82	$ -2.64	$ -2.06	$ -5.28	$ -0.92	$ -0.71
Diluted EPS	$ -2.82	$ -2.64	$ -2.06	$ -5.28	$ -0.92	$ -0.71
Basic Average Shares	$ 180.28M	$ 44.07M	$ 43.60M	$ 6.77M	$ 10.80M	$ 10.80M
Diluted Average Shares	$ 180.28M	$ 44.07M	$ 43.60M	$ 6.77M	$ 10.80M	$ 10.80M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 67.48M	$ -118.52M	$ -90.11M	$ 36.00M	$ 12.01M	$ 7.63M
Net Income From Continuing And Discontinued Operation	$ -127.21M	$ -116.32M	$ -89.80M	$ -35.76M	$ -11.97M	$ -7.63M
Normalized Income	$ -55.95M	-	-	$ -35.76M	$ -11.97M	$ -7.63M
Interest Expense	-	-	-	-	-	-
EBIT	$ -130.68M	$ -118.57M	$ -89.80M	$ -36.00M	$ -12.01M	$ -7.63M
EBITDA	$ -99.22M	$ -117.29M	$ -87.80M	$ -35.92M	$ -12.01M	$ -7.63M

Currency in USD

Kinnate Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing